Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $31.3333.

A number of research firms have commented on GLUE. Wells Fargo & Company boosted their price target on shares of Monte Rosa Therapeutics from $22.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, January 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research report on Monday, December 29th. Wedbush reissued an “outperform” rating and issued a $37.00 target price on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Jefferies Financial Group restated a “buy” rating and set a $31.00 price target on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Finally, Zacks Research cut Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 4th.

Monte Rosa Therapeutics Stock Down 4.1%

Monte Rosa Therapeutics stock opened at $17.75 on Monday. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of 55.47 and a beta of 1.63. The business has a 50-day simple moving average of $19.88 and a 200 day simple moving average of $13.68. Monte Rosa Therapeutics has a 52 week low of $3.50 and a 52 week high of $25.77.

Insider Transactions at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $23.49, for a total transaction of $128,396.34. Following the transaction, the chief executive officer directly owned 618,937 shares in the company, valued at $14,538,830.13. This trade represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Institutional investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP purchased a new position in Monte Rosa Therapeutics in the 4th quarter worth $63,000. Virtu Financial LLC grew its stake in shares of Monte Rosa Therapeutics by 56.6% during the fourth quarter. Virtu Financial LLC now owns 18,717 shares of the company’s stock valued at $293,000 after buying an additional 6,765 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Monte Rosa Therapeutics by 270.0% in the fourth quarter. Invesco Ltd. now owns 362,213 shares of the company’s stock worth $5,680,000 after buying an additional 264,315 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in shares of Monte Rosa Therapeutics in the 4th quarter valued at about $172,000. Finally, Empowered Funds LLC boosted its holdings in Monte Rosa Therapeutics by 218.0% during the 4th quarter. Empowered Funds LLC now owns 278,077 shares of the company’s stock valued at $4,360,000 after acquiring an additional 190,627 shares during the period. Hedge funds and other institutional investors own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.